Table 1 Patient characteristics and transplant-related parameters.

From: Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial

Variables

PTCy-ATG group (N = 53)

ATG group (N = 51)

P values

Median age in years (range)

29 (2–59)

29 (4–52)

0.969

Recipient sex

  

0.219

 Male

28 (52.8%)

33 (64.7%)

 

 Female

25 (47.2%)

18 (35.3%)

 

Disease type

  

0.362

 Acute myeloid leukemia (AML)

24 (45.3%)

31 (60.8%)

 

 Acute lymphoblastic leukemia (ALL)

22 (41.5%)

16 (31.4%)

 

 Myelodysplastic syndromes (MDS)

6 (11.3%)

4 (7.8%)

 

 CMML

1 (1.9%)

0

 

HCT-CI

  

0.843

 ≥3

8 (15.1%)

7 (13.7%)

 

 <3

45 (84.9%)

44 (86.3%)

 

Disease risk index

  

0.230

 Low/intermediate

26 (49.1%)

31 (60.8%)

 

 High/very high

27 (50.9%)

20 (39.2%)

 

Minimal residual disease at transplant

  

0.708

 Negative

30 (56.6%)

27 (52.9%)

 

 Positive

23 (43.4%)

24 (47.1%)

 

KPS

  

0.563

 <90

14 (26.4%)

11 (21.6%)

 

 ≥90

39 (73.6%)

40 (78.4%)

 

Donor sex

  

0.335

 Male

48 (90.6%)

43 (84.3%)

 

 Female

5 (9.4%)

8 (15.7%)

 

 Donor age (year, median, range)

30 (21-48)

31 (18-46)

0.862

Donor-recipient pair

  

0.513

 Female to female

2

2

 

 Female to male

3

6

 

 Male to female

23

16

 

 Male to male

25

27

 

Blood type matching

  

0.723

 Match

19 (35.8%)

20 (39.2%)

 

 Mismatch

34 (64.2%)

31 (60.8%)

 

 Median mononuclear cell (range, 108/kg)

11.07 (1.11–25.95)

11.12 (4.43–29.30)

0.592

 Median CD34 + cells (range, 106/kg)

6.57 (0.16–18.69)

6.4 (1.75–35.7)

0.709

 Median follow-up for survivors (range, days)

561 (182–1450)

600 (196–1370)

0.196

  1. PTCy post-transplant cyclophosphamide, ATG anti-thymocyte globulin, AML acute myelocytic leukemia, ALL acute lymphocyte leukemia, MDS myelodysplastic syndrome, CMML chronic myelomonocytic leukemia, HCT-CI hematopoietic cell transplantation-comorbidity index, KPS Kanofsky performance score.